Differential adoption of castration ‐resistant prostate cancer treatment across facilities in a national healthcare system

ConclusionMany facilities persisted in their use of ketoconazole as first-line CRPC therapy, even when other facilities had adopted the new standard of care abiraterone and enzalutamide. Further work is needed to identify the effect of this late adoption on outcomes important to patients.

Source: Cancer Medicine - February 16, 2023 Category: Cancer & Oncology Authors: Megan E. V. Caram, Kyle Kumbier, Jennifer Burns, Jordan B. Sparks, Phoebe A. Tsao, Kristian D. Stensland, Samuel L. Washington, Brent K. Hollenbeck, Vahakn Shahinian, Ted A. Skolarus Tags: RESEARCH ARTICLE Source Type: research